circIARS: a potential plasma biomarker for diagnosing non-small cell lung cancer

• circIARS is significantly upregulated in plasma and tissues of NSCLC patients, distinguishing them from healthy individuals, BPD, and SCLC patients. • circIARS expression decreases after antitumor therapy and increases upon recurrence, indicating its potential for dynamic monitoring. • ROC analysis shows circIARS has superior diagnostic efficiency compared to traditional markers. • circIARS is a stable and specific plasma biomarker, offering a minimally invasive adjunct for early NSCLC diagnosis and prognosis.